Author

K. Shirakawa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 9 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 9 Approach:experimental assay· 8 Organism:human· 8 Assay:proteomics· 3 Organism:virus· 2 Research Focus:cell type annotation· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Takaori-Kondo· 9 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 8 shared K. Sato· 7 shared K. Uriu· 7 shared Y. Kosugi· 7 shared I. Kimura· 6 shared A. Saito· 4 shared D. Yamasoba· 4 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

A. Takaori-Kondo

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Antiviral humoral immunity against SARS-CoV-2 Omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals

Y. Kosugi, Y. Kaku, A. A. Hinay, Z. Guo, K. Uriu, M. Kihara, F. Saito, Y. Uwamino, J. Kuramochi, K. Shirakawa, A. Takaori-Kondo, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

The paper assesses the humoral immune response to XBB.1.5 vaccine in infection-naive and XBB-infected individuals against various SARS-CoV-2 variants.

bioRxiv · Nov 29, 2023Microbiology

Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection

T. Tamura, H. Ito, S. Torii, L. Wang, S. Tsujino, A. Kamiyama, Y. Oda, Y. Morioka, S. Suzuki, K. Shirakawa, K. Sato, K. Yoshimatsu, Y. Matsuura, S. Iwano, S. Tanaka, T. Fukuhara

This study introduces AkaBLI, a method using Akaluc bioluminescence to track SARS-CoV-2 infection in vivo with higher sensitivity than NanoLuc, showing its utility in monitoring viral dynamics and vaccine efficacy.

bioRxiv · Oct 12, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75

A. Saito, T. Tamura, J. Zahradnik, S. Deguchi, K. Tabata, I. Kimura, J. Ito, H. Nasser, M. Toyoda, K. Nagata, K. Uriu, Y. Kosugi, S. Fujita, D. Yamasoba, M. Shofa, , Kei Sato

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

bioRxiv · Jul 14, 2022Microbiology

SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

I. Kimura, D. Yamasoba, H. Nasser, J. Zahradnik, Y. Kosugi, J. Wu, K. Nagata, K. Uriu, Y. L. Tanaka, J. Ito, R. Shimizu, T. S. Tan, E. P. Butlertanaka, H. Asakura, K. Sadamasu, , K. Sato

This study identifies the S375F mutation in the Omicron spike protein as responsible for its reduced cleavage efficiency, fusogenicity, and rapid spread.

bioRxiv · Apr 3, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

Characterization of the immune resistance of SARS-CoV-2 Mu variant and the immunity induced by Mu infection

K. Uriu, P. Cardenas, E. Munoz, V. Barragan, Y. Kosugi, K. Shirakawa, A. Takaori-Kondo, Ecuador-COVID19 Consortium, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study identifies mutations in the SARS-CoV-2 Mu variant responsible for its immune resistance and shows that Mu-infected convalescent sera are broadly antiviral.

bioRxiv · Nov 23, 2021Microbiology

Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera

K. Uriu, I. Kimura, K. Shirakawa, A. Takaori-Kondo, T.-a. Nakada, A. Kaneda, The Genotype to Phenotype Japan (G2P-Japan) Consortium, S. Nakagawa, K. Sato

This study shows that Mu variant is highly resistant to neutralization by convalescent and vaccine sera compared to other variants.

bioRxiv · Sep 6, 2021Microbiology

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

I. Kimura, Y. Kosugi, J. Wu, D. Yamasoba, E. P. Butlertanaka, Y. L. Tanaka, Y. Liu, K. Shirakawa, Y. Kazuma, R. Nomura, Y. Horisawa, K. Tokunaga, A. Takaori-Kondo, H. Arase, The Genotype to Phenotype Japan (G2P-Japan) Consortium, , K. Sato

The paper investigates the SARS-CoV-2 Lambda variant, finding it more infectious due to specific mutations and better immune evasion, contributing to its spread in South America.

bioRxiv · Jul 28, 2021Microbiology

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

A. Saito, T. Irie, R. Suzuki, T. Maemura, H. Nasser, K. Uriu, Y. Kosugi, K. Shirakawa, K. Sadamasu, I. Kimura, J. Ito, J. Wu, K. Iwatsuki-Horimoto, M. Ito, S. Yamayoshi, , K. Sato

This study shows the P681R mutation in the SARS-CoV-2 spike protein enhances fusogenicity and pathogenicity in the Delta variant compared to the prototypic virus.

bioRxiv · Jun 17, 2021Microbiology

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression

H. Yamazaki, K. Shirakawa, T. Matsumoto, Y. Kazuma, H. Matsui, Y. Horisawa, E. Stanford, A. D. Sarca, R. Shirakawa, K. Shindo, A. Takaori-Kondo

The paper develops APOBEC3B reporter myeloma cell lines to study DNA damage response pathways that regulate APOBEC3B expression, finding that conventional therapies increase its expression while targeted drugs do not.

bioRxiv · Sep 24, 2019Cancer Biology